Targeted Oncology

A handful of positive news highlights new treatments: Orca-T’s superior outcomes in hematologic malignancies, 225Ac-FL-020 receiving fast track for prostate cancer, the addition of glofitamab leading to greater efficacy in DLBCL, and real-world data demonstrating lenvatinib’s effectiveness in RAI-refractory thyroid cancer. https://lnkd.in/eUGMxigw

#FDA Update: The FDA granted SLS009 a rare pediatric disease designation for pediatric #AML, a fast track designation for DOC1021 for #PDAC, and placed a partial clinical hold on a phase 1 trial of seclidemstat in #MDS and #CMML. 1.https://https://lnkd.in/e5JMZ6Sx 2.https://https://lnkd.in/e2gDNd3Y 3.https://https://lnkd.in/erSPdtuU

Preventing recurrence of #RCC post-nephrectomy is crucial, with pembrolizumab showing survival benefits as adjuvant therapy, though patient selection for this treatment remains uncertain. #KCSM | Atrium Health, Fred Hutch, University of Utah Health https://lnkd.in/ezMC4PZn

In this episode of Targeted Talks, Omid Hamid, MD, delves into the mechanism of action, supporting data, and approval of lifileucel for the treatment of advanced #melanoma. #MELSM | The Angeles Clinic & Research Institute, Inc. https://lnkd.in/eeh5fJ_C

An investigational new drug application has been submitted to the #FDA for the phase 1/2 trial evaluating treatment with silmitasertib + chemotherapy for pediatric and young adult patients with relapsed/refractory solid tumors. https://lnkd.in/eZtmSZeu

The #FDA has granted DSP-5336 a fast track designation, supported by updated findings from an ongoing phase 1/2 study. #AML #LEUSM https://lnkd.in/g_kiQkZJ

Need a refresher on recent lung cancer research developments? In a recent interview, Aakash Desai, MD, MPH, spoke with Targeted Oncology about the advancements in lung cancer treatment highlighted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Here's an overview: ✔ Trials like PACIFIC, LAURA, and CROWN have paved the way for new and potential therapeutic options for patients with oncogene-driven NSCLC. ✔ Lorlatinib (Lobrena) has shown remarkable results, stopping lung cancer growth for 5 years or more in over half of patients with advanced NSCLC and an ALK gene mutation. ✔ The ADRIATIC study revealed promising outcomes for patients with limited-stage SCLC. At a median follow-up of 37.2 months, durvalumab (Imfinzi) led to a 27% reduction in the risk of death compared to placebo. You can read the full article for more details. These advancements promise better outcomes and survival rates. Do you have an idea for a clinical trial? Contact us, and let's talk. Let's cure lung cancer together! #lungcancer #oncology #cancer https://lnkd.in/gjACiupy

Expanding Treatment Options in Urothelial Cancer With #ADCs 👇 Targeted Oncology discuss the potential benefits of antibody-drug conjugates in urothelial cancer while acknowledging the need for more education and experience among physicians to optimize their use. Click the link below to watch the video 🔗 https://lnkd.in/e52F-vWx

July is #SarcomaAwarenessMonth. Elizabeth Loggers, MD, PhD, discussed the phase 3 DeFi study exploring ovarian toxicity in female patients receiving nirogacestat for the treatment of desmoid tumors. Fred Hutch https://lnkd.in/e46xUZ94

Dr. Ballinger Shares Her Top News From #ASCO24. Watch now! https://lnkd.in/eQMQnfMQ